The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,385,600 in first-year total cost, median $692,800.
Most frequent study sections
- Neurological Sciences and Disorders B Study Section[NSD-B]2
Most frequent institutions
- AMPRION, INC.1
- PROTEGO BIOPHARMA, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR)1U44NS114151-01 | JIANG, XIN | PROTEGO BIOPHARMA, INC., CA | $700,000 | NSD |
| 2020 | Analytical validation of a biochemical test for alpha-synuclein aggregates in biological fluids for the diagnosis of Parkinson's Disease1U44NS111672-01A1 | MACLEOD, KAREN | AMPRION, INC., CA | $685,600 | NSD |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.